Table: Peptidream -Q1 group results (IFRS)
May 14 (Reuters)-
Peptidream Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Mar 31, 2024 Mar 31, 2023 Dec 31, 2024
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 4.23 4.96 45.00
(-14.9 pct) (+56.7 pct)
Operating loss 1.10 loss 266 mln 20.10
(+196.8 pct)
Pretax loss 1.10 loss 399 mln 19.90
(+357.1 pct)
Net loss 842 mln loss 248 mln 14.00
(+361.2 pct)
EPS Basic loss 6.50 yen loss 1.92 yen
EPS Diluted loss 6.50 yen loss 1.92 yen
Ann Div NIL NIL
-Q2 Div NIL NIL
-Q4 Div NIL NIL
NOTE - Peptidream Inc..
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4587.T
Recent news on PeptiDream
See all newsTable: Peptidream 6-MTH group results (IFRS)
Brief: Peptidream Inc. - Initiation Of Phase 1 Clinical Trial By Novartis Marks Milestone For Peptidream
Brief: PeptiDream Announces First Dosing Of 64cu-Pd-29,875 In Gastric Cancer Patients
Table: Peptidream -Q1 group results (IFRS)
Brief: Peptidream Announces The Initiation Of Phase 1 Clinical Trial By Its Collaboration Partner